RNA interference (RNAi)

Wool heart
Favicon Fierce Biotech

Don't count out Alnylam's next-gen silencer in ATTR-CM: analysts

Patients' disease stage, transthyretin knockdown levels and trial design have become focal points in debates around silencer-stabilizer combos.
Space shuttle takes off on background of blue sky

As questions swirl, Alnylam eyes ATTR market leadership by 2030

Mar 26, 2026 2:08pm
Asia

OX40, Roche-Sanegene, Daiichi—Fierce Pharma Asia

Feb 6, 2026 9:48am
Massachusetts Massachusetts flag MA MA flag

Alnylam drafts $250M upgrade to its Mass. drug factory

Dec 17, 2025 10:12am
Alnylam

Alnylam's ATTR-CM launch blows past estimates again

Oct 30, 2025 8:00am
Space shuttle takes off on background of blue sky

Alnylam's market cap jumps past $50B

Aug 1, 2025 7:39am